210 related articles for article (PubMed ID: 29272692)
21. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
Psoni S; Sofocleous C; Traeger-Synodinos J; Kitsiou-Tzeli S; Kanavakis E; Fryssira-Kanioura H
Brain Dev; 2012 Jun; 34(6):487-95. PubMed ID: 21982064
[TBL] [Abstract][Full Text] [Related]
22. Whole brain delivery of an instability-prone
Luoni M; Giannelli S; Indrigo MT; Niro A; Massimino L; Iannielli A; Passeri L; Russo F; Morabito G; Calamita P; Gregori S; Deverman B; Broccoli V
Elife; 2020 Mar; 9():. PubMed ID: 32207685
[TBL] [Abstract][Full Text] [Related]
23. Selective preservation of cholinergic MeCP2 rescues specific Rett-syndrome-like phenotypes in MeCP2
Zhou H; Wu W; Zhang Y; He H; Yuan Z; Zhu Z; Zhao Z
Behav Brain Res; 2017 Mar; 322(Pt A):51-59. PubMed ID: 28093257
[TBL] [Abstract][Full Text] [Related]
24. Treating Rett syndrome: from mouse models to human therapies.
Vashi N; Justice MJ
Mamm Genome; 2019 Jun; 30(5-6):90-110. PubMed ID: 30820643
[TBL] [Abstract][Full Text] [Related]
25. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution.
Kaufmann WE; Johnston MV; Blue ME
Brain Dev; 2005 Nov; 27 Suppl 1():S77-S87. PubMed ID: 16182491
[TBL] [Abstract][Full Text] [Related]
26. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.
Garg SK; Lioy DT; Cheval H; McGann JC; Bissonnette JM; Murtha MJ; Foust KD; Kaspar BK; Bird A; Mandel G
J Neurosci; 2013 Aug; 33(34):13612-20. PubMed ID: 23966684
[TBL] [Abstract][Full Text] [Related]
27. RNA sequencing and proteomics approaches reveal novel deficits in the cortex of
Pacheco NL; Heaven MR; Holt LM; Crossman DK; Boggio KJ; Shaffer SA; Flint DL; Olsen ML
Mol Autism; 2017; 8():56. PubMed ID: 29090078
[TBL] [Abstract][Full Text] [Related]
28. Disruption of MeCP2 attenuates circadian rhythm in CRISPR/Cas9-based Rett syndrome model mouse.
Tsuchiya Y; Minami Y; Umemura Y; Watanabe H; Ono D; Nakamura W; Takahashi T; Honma S; Kondoh G; Matsuishi T; Yagita K
Genes Cells; 2015 Dec; 20(12):992-1005. PubMed ID: 26456390
[TBL] [Abstract][Full Text] [Related]
29. Reversibility of functional deficits in experimental models of Rett syndrome.
Cobb S; Guy J; Bird A
Biochem Soc Trans; 2010 Apr; 38(2):498-506. PubMed ID: 20298210
[TBL] [Abstract][Full Text] [Related]
30. MeCP2 SUMOylation rescues Mecp2-mutant-induced behavioural deficits in a mouse model of Rett syndrome.
Tai DJ; Liu YC; Hsu WL; Ma YL; Cheng SJ; Liu SY; Lee EH
Nat Commun; 2016 Feb; 7():10552. PubMed ID: 26842955
[TBL] [Abstract][Full Text] [Related]
31. RettBASE: Rett syndrome database update.
Krishnaraj R; Ho G; Christodoulou J
Hum Mutat; 2017 Aug; 38(8):922-931. PubMed ID: 28544139
[TBL] [Abstract][Full Text] [Related]
32. The story of Rett syndrome: from clinic to neurobiology.
Chahrour M; Zoghbi HY
Neuron; 2007 Nov; 56(3):422-37. PubMed ID: 17988628
[TBL] [Abstract][Full Text] [Related]
33. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains.
Itoh M; Ide S; Takashima S; Kudo S; Nomura Y; Segawa M; Kubota T; Mori H; Tanaka S; Horie H; Tanabe Y; Goto Y
J Neuropathol Exp Neurol; 2007 Feb; 66(2):117-23. PubMed ID: 17278996
[TBL] [Abstract][Full Text] [Related]
34. Proteomic analysis of the Rett syndrome experimental model mecp2
Cortelazzo A; Pietri T; De Felice C; Leoncini S; Guerranti R; Signorini C; Timperio AM; Zolla L; Ciccoli L; Hayek J
J Proteomics; 2017 Feb; 154():128-133. PubMed ID: 28062374
[TBL] [Abstract][Full Text] [Related]
35. miR-199a Links MeCP2 with mTOR Signaling and Its Dysregulation Leads to Rett Syndrome Phenotypes.
Tsujimura K; Irie K; Nakashima H; Egashira Y; Fukao Y; Fujiwara M; Itoh M; Uesaka M; Imamura T; Nakahata Y; Yamashita Y; Abe T; Takamori S; Nakashima K
Cell Rep; 2015 Sep; 12(11):1887-901. PubMed ID: 26344767
[TBL] [Abstract][Full Text] [Related]
36. The ups and downs of BDNF in Rett syndrome.
Sun YE; Wu H
Neuron; 2006 Feb; 49(3):321-3. PubMed ID: 16446133
[TBL] [Abstract][Full Text] [Related]
37. MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotype-phenotype correlations and validation of high-resolution melting analysis for mutation scanning.
Zahorakova D; Lelkova P; Gregor V; Magner M; Zeman J; Martasek P
J Hum Genet; 2016 Jul; 61(7):617-25. PubMed ID: 26984561
[TBL] [Abstract][Full Text] [Related]
38. BDNF deregulation in Rett syndrome.
Li W; Pozzo-Miller L
Neuropharmacology; 2014 Jan; 76 Pt C(0 0):737-46. PubMed ID: 23597512
[TBL] [Abstract][Full Text] [Related]
39. Generation and analysis of the Rett syndrome-associated MeCP2- null rat model.
Zhai W; Hu HX; Le L; Zhuang FF; Wang KZ; Zhao Y; Wang K; Liu XM; Sun D; Wang XY; Kuang SH; Hu KP
Yi Chuan; 2016 Nov; 38(11):1004-1011. PubMed ID: 27867150
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice.
Lo FS; Blue ME; Erzurumlu RS
J Neurophysiol; 2016 Mar; 115(3):1298-306. PubMed ID: 26683074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
